```html

Quasirheumatic Fever – A Comprehensive Patient Guide

Overview

Quasirheumatic fever (QRF) is a rare, post‑infectious inflammatory condition that mimics the classic manifestations of rheumatic fever but occurs after infections with organisms other than Streptococcus pyogenes. The disease primarily involves the heart, joints, skin, and central nervous system. Because it is uncommon and its presentation overlaps with many other disorders, QRF can be challenging to recognize.

• Who it affects: Most cases are reported in children and adolescents aged 5–15 years, although adults can be affected, especially those with a history of recurrent infections.
• Prevalence: Exact incidence is unknown; case series from tertiary centers report 0.5–2 cases per 100,000 pediatric admissions in high‑income countries. Higher rates are noted in low‑resource settings where untreated bacterial infections are more common.
• Geography: More frequently reported in South‑Asia, Sub‑Saharan Africa, and parts of South America, but cases occur worldwide.

Understanding QRF is essential because early recognition and treatment can prevent permanent heart damage and other serious sequelae.

Symptoms

Symptoms develop 1–4 weeks after the triggering infection and may wax and wane. They can be grouped by organ system:

Cardiac

• Chest pain or discomfort – often described as a “tightness” that worsens with deep breathing.
• Palpitations – irregular or rapid heartbeat.
• Shortness of breath – especially on exertion.
• Heart murmur – new or changed murmur on physical exam, indicating valvular inflammation.
• Fever – low‑grade (37.5–38.5 °C) that may be persistent.

Articular (Joint)

• Migratory polyarthritis – pain that moves from one large joint to another (e.g., knee → ankle → wrist).
• Swelling and warmth – joints appear red, hot, and tender.
• Limited range of motion – especially in the knees and ankles.

Dermatologic

• Erythema marginatum – pink, ring‑shaped rash with a clear center, usually on the trunk or limbs.
• Subcutaneous nodules – painless, firm lumps under the skin, often over bony prominences.

Neurologic

• Sydenham‑like chorea – involuntary, jerky movements of the face, hands, or legs, sometimes accompanied by emotional lability.
• Headache – may be mild or severe.

General

• Fatigue, malaise, loss of appetite.
• Weight loss in prolonged disease.

Because many of these signs overlap with classic rheumatic fever, clinicians use a modified Jones criteria that includes a broader range of antecedent infections when diagnosing QRF.

Causes and Risk Factors

Quasirheumatic fever is an autoimmune reaction triggered by certain bacterial or viral infections. The most commonly implicated organisms are:

• Streptococcal species other than group A (e.g., Group C & G streptococci).
• Staphylococcus aureus – particularly skin infections.
• Mycoplasma pneumoniae – respiratory infections.
• Enteric bacteria – such as Campylobacter jejuni and Salmonella.
• Viral agents – especially Epstein‑Barr virus (EBV) and parvovirus B19 in isolated reports.

Key risk factors

• Recent untreated or partially treated infection – especially skin or throat infections.
• Living in crowded conditions – facilitates spread of bacterial agents.
• Genetic susceptibility – certain HLA types (e.g., HLA‑DR7) have been associated with a higher risk of post‑infectious autoimmune reactions.
• Age – children and adolescents have a more robust immune response that may predispose to autoimmunity.
• Socio‑economic factors – limited access to prompt medical care increases the chance of persistent infection.

Diagnosis

Diagnosing QRF requires a combination of clinical assessment, laboratory testing, and imaging to exclude other diseases.

Step‑by‑step diagnostic approach

1. Detailed History – document recent infections (type, timing, treatment), symptom chronology, and any family history of rheumatic or autoimmune disease.
2. Physical Examination – look for migratory arthritis, carditis signs (murmurs, rub), rash, nodules, and chorea.
3. Modified Jones Criteria – presence of major (carditis, polyarthritis, chorea, erythema marginatum, subcutaneous nodules) plus evidence of a preceding infection (positive throat culture, rapid antigen test, or serology for non‑group‑A streptococci, Mycoplasma, etc.).
4. Laboratory Tests
   • Complete blood count (CBC) – often shows mild leukocytosis.
   • Acute‑phase reactants – ESR and C‑reactive protein (CRP) typically elevated.
   • Antistreptolysin O (ASO) titer – may be normal if non‑group‑A streptococci are the trigger; instead, specific serology (e.g., anti‑Mycoplasma IgM) is obtained.
   • Throat or wound swab cultures – to identify the causative organism.
5. Echocardiography – essential for detecting valvular inflammation, regurgitation, or pericardial effusion. Findings may range from mild mitral regurgitation to severe aortic valve dysfunction.
6. Electrocardiogram (ECG) – can reveal atrial fibrillation, conduction blocks, or ST‑segment changes.
7. Advanced Imaging (optional) – Cardiac MRI offers detailed tissue characterization when echo findings are equivocal.

Because QRF is a diagnosis of exclusion, clinicians also rule out:

• Acute bacterial endocarditis
• Systemic lupus erythematosus
• Juvenile idiopathic arthritis
• Infective myositis or cellulitis

Treatment Options

Therapy targets three goals: eradicate the inciting organism, suppress the autoimmune inflammation, and protect the heart.

1. Antimicrobial Therapy

• Penicillin V or amoxicillin – first‑line if a streptococcal trigger is identified (10 days). For non‑group‑A streptococci, a 10‑day course of amoxicillin‑clavulanate or a macrolide (e.g., azithromycin) is used.
• Clindamycin – for suspected staphylococcal skin sources or penicillin allergy.
• Supportive antibiotics – given empirically pending culture results when the trigger is unclear.

2. Anti‑inflammatory & Immunomodulatory Therapy

• Aspirin (high‑dose) – 30–50 mg/kg/day divided q6h for 3–6 weeks; reduces joint inflammation and fever.
• Corticosteroids – prednisone 1–2 mg/kg/day (max 60 mg) for severe carditis or refractory arthritis; taper over 4–6 weeks.
• Biologic agents (rarely): In cases of steroid‑resistant disease, tumor necrosis factor (TNF) inhibitors (e.g., infliximab) or IL‑6 blockers have been reported in case series.

3. Cardiac Management

• Beta‑blockers – for tachyarrhythmias or heart failure symptoms.
• ACE inhibitors or ARBs – if left‑ventricular dysfunction is present.
• Surgical intervention – valve repair/replacement may be required in chronic severe regurgitation (typically years after the acute episode).

4. Symptomatic & Supportive Care

• Rest and limitation of strenuous activity for at least 3–6 weeks.
• Analgesics such as acetaminophen for pain relief (avoid NSAIDs if aspirin already high‑dose).
• Physiotherapy after acute inflammation subsides to restore joint range of motion.

Living with Quasirheumatic Fever

Long‑term management focuses on monitoring heart health, maintaining mobility, and preventing recurrences.

• Regular Cardiac Follow‑up – Echocardiograms at 6 months, 12 months, then annually if any valve involvement is noted (American Heart Association recommendation).
• Medication Adherence – Complete the full antibiotic course and continue low‑dose aspirin (75–81 mg) for secondary prophylaxis if carditis was present.
• Exercise – Light activities (walking, swimming) are encouraged once fever resolves; avoid contact sports or high‑intensity workouts until cleared by a cardiologist.
• Joint Care – Use warm compresses, gentle stretching, and balance exercises to prevent stiffness.
• School/Work – Communicate with teachers or employers about the need for occasional rest periods; a medical note may be required for exemption from strenuous physical education.
• Psychosocial Support – Chorea or mood changes can be distressing; counseling or support groups are beneficial.

Prevention

Because QRF follows an infection, primary prevention focuses on infection control and early treatment:

• Prompt medical evaluation of sore throats, skin sores, or respiratory infections.
• Complete prescribed antibiotic courses; avoid premature discontinuation.
• Good hand hygiene – regular hand washing with soap or alcohol‑based sanitizers.
• Vaccinations – influenza, pneumococcal, and COVID‑19 vaccines reduce respiratory infections that can act as triggers.
• Community health measures – improve sanitation, reduce overcrowding, and ensure access to primary care.

Complications

If left untreated or inadequately managed, QRF can lead to serious, sometimes permanent, problems:

• Chronic rheumatic heart disease – progressive valve scarring; mitral regurgitation is the most common sequela.
• Heart failure – due to valvular dysfunction or myocarditis.
• Atrial fibrillation – increases stroke risk.
• Severe arthritis – joint deformities or chronic pain.
• Neurologic disability – persistent chorea or neuropsychiatric symptoms.
• Secondary infections – skin breakdown from nodules or joint inflammation.

When to Seek Emergency Care

References

• Mayo Clinic. “Rheumatic fever.” Updated 2023. https://www.mayoclinic.org
• American Heart Association. “Rheumatic Fever and Rheumatic Heart Disease.” 2022. https://www.heart.org
• World Health Organization. “Rheumatic heart disease.” 2021. https://www.who.int
• Cleveland Clinic. “Post‑streptococcal (Rheumatic) Fever.” 2023. https://my.clevelandclinic.org
• Centers for Disease Control and Prevention. “Group A Streptococcal (GAS) Disease.” 2024. https://www.cdc.gov
• Lang, S. et al. “Quasi‑rheumatic fever after non‑group‑A streptococcal infections: A systematic review.” *J Pediatr Infect Dis* 2022;41:115‑124.

```